Lung-RADS 3 | Â | Â |
 | Black Patients n = 21 | White Patients n = 22 |
Mean Age ± SD | 65.1 ± 5.7 | 65.1 ± 5.0 |
Sex | ||
• Female | 11 (52.4%) | 8 (36.4%) |
• Male | 10 (47.6%) | 14 (63.6%) |
Overall adherencea, n (%) | 19 (90.5%) | 20 (90.9%) |
Time to follow-up CTb, mean mos ± SD | 8.5 ± 4.5 | 6.6 ± 3.0 |
Timely adherencec, n (%) | 12 (63.2%) | 16 (80.0%) |
Screen-detected cancer | 2 (9.1%) | 0 (0%) |
Patients eligible for screening or nodule surveillance | 18d | 21e |
• Return to annual screening or nodule surveillance | 11 (61.1%) | 12 (57.1%) |
• Lost to follow-upf | 7 (38.9%) | 9 (42.9%) |
Lung-RADS 4 | ||
 | Black Patients n = 14 | White Patients n = 13 |
Mean Age ± SD | 688 ± 5.8 | 65.2 ± 4.3 |
Sex | ||
• Female | 5 (35.7%) | 3 (23.1%) |
• Male | 9 (64.3%) | 10 (76.9%) |
Overall adherencea, n (%) | 14 (100%) | 13 (100%) |
Time to follow-up CTb, mean mos ± SD | 3.1 ± 2.9 | 2.1 ± 1.5 |
Timely adherencec, n (%) | 10 (71.4%) | 10 (76.9%) |
Screen-detected cancer | 5 (35.7%) | 3 (30.8%) |
Patients eligible for screening or nodule surveillance | 9 | 9 |
• Return to annual screening or nodule surveillance | 3 (33.3%) | 6 (66.7%) |
• Lost to follow-upf | 6 (66.7%) | 3 (33.3%) |